Response to isoproterenol as a prognostic indicator of evolution from hypertrophic cardiomyopathy to a phase resembling dilated cardiomyopathy  by Kawano, Satoru et al.
JACC Vol. 25, No. 3 687 
March 1, t995:687-92 
Response to Isoproterenol as a Prognostic Indicator of Evolution 
From Hypertrophic Cardiomyopathy to a Phase Resembling 
Dilated Cardiomyopathy 
SATORU KAWANO,  MD, KEIJ I  I IDA, MD, KATSUJ I  FU J IEDA,  MD, K IMIH IKO YUKISADA,  MD, 
EL SERSI MAGDI ,  MD, YUKO IWASAKI,  MD, FUMIKO TABEI,  MD, IWAO YAMAGUCHI ,  MD, 
YASURO SUGISHITA,  MD, FACC 
Tsukuba, Ibaraki, Japan 
Objectives. We sought to assess whether isoproterenol stress 
echocardiography could detect in advance in which patients 
hypertrophic cardiomyopathy would progress to a phase resem- 
bling dilated cardiomyopathy. 
Background. In a few patients, hypertrophic cardiomyopathy 
has been reported to progress to a phase characterized by systolic 
dysfunction and left ventricular dilation, resembling dilated car- 
diomyopathy. 
Methods. Echocardiograms were recorded before and immedi- 
ately after intravenous infusion of isoproterenol (0.02 #g/kg body 
weight per min) for 5 min in 18 patients with typical hypertrophic 
cardiomyopathy (i.e., hypertrophied, hyperdynamic and nondi- 
lated) to determine the difference in fractional shortening. The 
patients were categorized into those with a good response (differ- 
ence in fractional shortening >7%, 14 patients) and those with a 
poor response (difference <7%, 4 patients). Changes in left 
ventricular end-diastolic diameter and fractional shortening were 
evaluated by using serial echocardiography over an average 
follow-up period of 5.4 years. 
Results. In the good response group, neither end-diastolic 
diameter nor fractional shortening changed significantly during 
the follow-up period. In the poor response group, end-diastolic 
diameter significantly increased from a mean + SD of 41 -+ 5 to 
53 -+ 5 mm (p < 0.05), and fractional shortening significantly 
decreased from 40 _+ 12% to 29 -+ 10% (p < 0.05). All patients in 
the poor response group showed a substantial decrease (>5%) in 
fractional shortening and an increase (>5 mm) in end-diastolic 
diameter. One patient developed congestive heart failure due to 
systolic dysfunction during the observation period. 
Conclusions. The present study confirmed that impaired re- 
sponses to isoproterenol infusion are related to future deteriora- 
tion of left ventricular performance in patients with typical 
hypertrophic cardiomyopathy. 
(J Am CoU Cardiol 1995;25:687-92) 
Hypertrophic cardiomyopathy and dilated cardiomyopathy are 
presumed to be different entities. In most patients with hyper- 
trophic cardiomyopathy, left ventricular systolic function is 
normal or supernormal. However, in a few patients, hypertro- 
phic cardiomyopathy as been reported to progress to a state 
that is characterized by systolic dysfunction and left ventricular 
dilation and resembles dilated cardiomyopathy (1-7). Predic- 
tion of the evolution to this phase is difficult. In a previous 
study, we (8) reported hypersensitivity of the beta-adrenergic 
receptor system in patients with hypertrophic cardiomyopathy 
and asymmetric septal hypertrophy. However, some of these 
patients howed less response to beta-adrenergic stimulation 
than that of normal control subjects. The reduced response to 
isoproterenol might have been due to myocardial damage 
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caused by ischemia, fibrosis or other factors. In the present 
study, to assess the relation between the capacity of the left 
ventricle to respond to stimulation with a beta-adrenergic 
agonist and prognosis or functional changes of the left ventri- 
cle, we performed isoproterenol stress echocardiography in 18 
patients with hypertrophic ardiomyopathy and monitored 
them with the use of serial echocardiography. We investigated 
whether isoproterenol stress echocardiography could predict in 
which patients hypertrophic cardiomyopathy would evolve into 
a phase resembling dilated cardiomyopathy. 
Methods  
Patient selection. Forty-four patients with hypertrophic 
cardiomyopathy were included in the study. The diagnosis of 
hypertrophic cardiomyopathy was based on findings obtained 
at echocardiography and cardiac catheterization according to 
the following criteria: 1) hypertrophied but nondilated left 
ventricle; 2) normal or supernormal left ventricular ejection 
fraction; 3) absence of valvular disease, cardiac amyloidosis or 
any other systemic ause of hypertrophy, including hyperten- 
sion, that could produce secondary left ventricular hypertro- 
phy. Patient exclusion criteria for isoproterenol stress echocar- 
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diography and the follow-up studies were 1) overt heart failure; 
2) severe mitral regurgitation; 3) uncontrolled cardiac arrhyth- 
mia; 4) conditions in which withdrawal of medication was 
considered unacceptable; 5) other major systemic diseases, 
including diabetes mellitus and alcohol abuse; 6) poor echo- 
cardiographic tracing. Of 44 patients with hypertrophic car- 
diomyopathy included in the study, 26 were excluded on the 
basis of the exclusion criteria. Thus, 18 patients were analyzed 
to assess the morphologic and functional changes of the left 
ventricle. The study group included 1 patient with obstructive 
hypertrophic cardiomyopathy (this patient had no left ventric- 
ular outflow pressure gradient at rest; obstruction was pro- 
voked only by the premature beats), 12 patients with nonob- 
structive hypertrophic cardiomyopathy and 5 patients with 
apical hypertrophic cardiomyopathy. Four patients had epi- 
sodes of chest pain; however, none of the four demonstrated 
ischemic ST segment depression after the exercise stress test. 
All patients included in the follow-up study had cardiac 
catheterization, and all patients in the poor response group 
also underwent coronary angiography. No coronary stenosis 
>25% was demonstrated in these patients. 
At the time of the first isoproterenol echocardiographic 
stress test, the mean age of the patients was 54 years (range 40 
to 70). Fifteen patients (83%) were male. Four patients (22%) 
had a family history of left ventricular hypertrophy and sudden 
death. No patient had had an episode of heart failure, and all 
were in New York Heart Association functional class i. 
Beta-adrenergic blocking agents (propranolol, carteolol, 
atenolol) had been administered for therapeutic reasons to 
three patients, calcium channel antagonists (nifedipine, dilti- 
azem) to six, and both types of drugs to five; 5 patients had 
received neither of these drugs. All drugs were discontinued 
for at least 24 h before the echocardiographic study. The 
patients did not take beta-blockers the day before the isopro- 
terenol stress test. 
Echocardiographic study. Real-time two-dimensional and 
M-mode echocardiograms were recorded using a Toshiba 
SSH-11A or 65A ultrasound apparatus with a 2.25- or 3.5-MHz 
transducer. The recordings of M-mode echocardiograms were 
made with a strip chart recorder at a paper speed of 50 ram/s, 
together with electrocardiograms (ECGs) and phonocardio- 
grams. Echocardiograms were obtained with patients in a 
slightly left lateral position. The transducer was placed over the 
left third or fourth intercostal space at the sternal margin. Left 
ventricular echocardiograms were recorded at the level of the 
chordae tendineae below the tips of the mitral leaflets under 
monitoring of two-dimensional echocardiograms. Each record 
was obtained during expiration. The left ventricular end- 
diastolic dimension was measured at the peak of the R wave on 
the ECG and the end-systolic dimension at the time of the 
second heart sound. Fractional shortening was calculated as 
(End-diastolic dimension [mm] - End-systolic dimension 
[mm])/End-diastolic dimension (ram) × 100 (%). The thick- 
ness of the interventricular septum and posterior left ventric- 
ular wall thickness at end-diastole were measured on a strip 
chart. In all cases, echocardiograms were analyzed indepen- 
dently by two observers. 
Isoproterenol stress echocardiography. Isoproterenol 
stress echocardiography was performed within i year after the 
initial diagnosis of hypertrophic cardiomyopathy. This tech- 
nique has been described previously (8-10). Briefly, the pa- 
tient lay in the supine position in a darkened room and 
isoproterenol was infused intravenously for 5 min through an 
antecubital vein at a dose of 0.02/zg/kg per min by means of a 
calibrated infusion pump. Blood pressure was measured with a 
cuff and mercury column sphygmomanometer at est and 
during isoproterenol infusion every 1 min. M-mode echocar- 
diography was performed before and immediately after isopro- 
terenol infusion and was recorded on a strip chart at 50 mm/s. 
End-diastolic dimension and fractional shortening were ob- 
tained, and the change in fractional shortening with isoproter- 
enol was determined. In a previous tudy, 10 normal control 
subjects underwent isoproterenol stress echocardiography to 
establish this criterion. We (8) demonstrated that at a dose of 
isoproterenol 0.02 /xg/kg per min the change in fractional 
shortening in normal control subjects was 13 _+ 3%. In the 
present study, the criterion of poor response to isoproterenol 
was defined as -<7% (mean value of normal control subjects 
minus 2 SD). The patients were classified into two groups: 
patients with a good response (change in fractional shortening 
>7%) and those with a poor response (change <-7%). 
Follow-up studies. After initial evaluation by isoproterenol 
stress echocardiography, all the patients were followed up at 
Tsukuba University Hospital for ->2 years; the maximal 
follow-up period was 10 years. A family history was obtained 
from all patients. Clinical findings, New York Heart Associa- 
tion functional class and ECGs were repeatedly examined 
during follow up. The changes in end-diastolic dimension, 
fractional shortening, interventricular septal thickness and 
posterior left ventricular wall thickness were evaluated with the 
use of serial echocardiography. We defined wall thinning and 
left ventricular dilation as a change ->5 ram. This cutoff value 
was selected in consideration of the image resolution limita- 
tions of echocardiography and to minimize false positive 
diagnoses (11). 
To assess the variability in interpretation, all echocardio- 
grams were analyzed independently by two observers. To 
determine variability in the interpretation byone observer, the 
same sets of recordings were evaluated again by each observer 
>2 weeks after the initial evaluation. The reproducibility ofthe 
measurements was calculated on the basis of standard error of 
the estimate; both intraobserver and interobserver variation 
were 10%. 
Statistical analysis. Data are presented as the mean value 
_+ 1 SD. Significance of differences between means was deter- 
mined by using the unpaired or paired Student test where 
appropriate. Differences inproportions were analyzed with the 
Fisher exact probability test. Statistical calculations were per- 
formed by using Statview software. A p value -<0.05 was 
considered statistically significant. 
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Table 1. Hemodynamic Data Before and After lsoproterenol Infusion 
HR (beats/min) SBP (mm Hg) DBP (mm Hg) 
Response 
Group Before After ISP Before After ISP Before After ISP 
Good 67 + 9 104 + 15 136 + 13 151 ± 13 83 + l0 74 ± 1} 
Poor 67 _+ 9 106 ± 11 122 ± 12 }ll ± 21' 80 ± 8 70 + 13 
*p < 0.05 versus good response group. Data are presented as the mean value + 1 SD. DBP = diastolic blood 
pressure; HR = heart rate; ISP = isoproterenol; SBP = systolic blood pressure. 
Resu l ts  
Isoproterenol stress echocardiography. The change in 
fractional shortening with isoproterenol ranged from 4% to 
27%. Four of the 18 patients were included in the poor 
response group (mean change in fractional shortening 6 _+ 1%) 
according to the preceding definition; 14 were included in the 
good response group (mean change 15 _+ 6%). The mean age 
of the poor response group was 54 _+ 5 years; that of the good 
response group was 55 _+ 9 years (p = NS). The hemodynamic 
data before and during isoproterenol infusion in both groups 
are given in Table 1. Before isoproterenol infusion, heart rate 
and systolic and diastolic blood pressure in the two groups 
were not significantly different. After isoproterenol infusion, 
systolic blood pressure was significantly lower in the poor 
response group (p < 0.05), a result suggesting latent impair- 
ment of left ventricular performance in this group. However, 
there were no significant differences in heart rate and diastolic 
blood pressure during isoproterenol infusion between the two 
groups. 
Serial eehoeardiographic follow-up study. Table 2 summa- 
rizes data from the serial echocardiographic follow-up study. 
The mean follow-up period was 5.2 _+ 2.1 years in the good 
response group and 6.0 +_ 0.4 years in the poor response group 
(p = NS). 
Changes in left ventricular hypertrophy. At the initial evalu- 
ation, there were no significant differences in interventricular 
septal thickness (18 _+ 5 vs. 23 _+ 7 ram) or posterior left 
ventricular wall thickness (14 _+ 5 vs. 13 + 2 mm) between the 
Table 2. Serial Echocardiographic Findings at Baseline and at the End of Follow-Up 
Dd (mm) FS (%) IVST (mm) PWT (mm) 
Pt AFS Follow-Up End of End of End of End of 
No. (%) Period (yr)  Basel ine Follow-Up Basel ine Follow-Up Basel ine Follow-Up Baseline Follow-Up 
Good Response Group 
1 8 5.5 47 46 34 39 17 16 15 15 
2 8 7.6 46 47 52 61 18 17 11 12 
3 9 5.5 50 45 46 42 30 27 12 9 
4 9 5.8 46 43 50 47 16 16 11 11 
5 13 6.(I 45 44 55 52 20 19 16 17 
6 13 2.0 43 43 35 42 } 6 14 12 12 
7 19 5.7 40 39 38 41 17 14 16 13 
8 14 2.0 43 38 44 45 20 18 11 10 
9 14 4.7 49 51 43 49 19 18 16 12 
10 17 3.5 48 44 33 32 16 18 12 10 
11 19 5.7 44 39 42 41 24 20 14 13 
12 21 10.(} 46 47 33 40 14 13 11 13 
13 22 5.5 43 41 47 46 14 16 18 13 
14 27 3.2 47 50 45 50 13 13 II 12 
Mean ± SD 15 ± 6* 5.2 ± 2.1 46 = 3t 44 ± 4* 43 + 7 45 + 7' 18 z 5 17 + 4 13 ± 2 12 ± 2 
Poor Response Group 
15 4 5.8 48 53 33 26 16 15 It 13 
16 5 5.5 38 49 42 35 32 20 ~) 13 
17 6 6.3 38 59 29 17 25 12 10 10 
18 7 6.2 41 49 56 39 20 16 15 13 
Mean±SD 6±1 6.(}+0.4 41±5 53±5~ 40~12 29±10t 23+7 16±3 14+5 12±2 
*p < 0.01 versus poor response group. +p < (I.05 versus poor response group. ~p < 0.05 versus baseline value. Dd = left ventricular end-diastolic dimension; 
AFS = change in fractional shortening with isoprotcrcnol; FS = fractional shortening; IVST = intcrvcntricular septal thickness; Pt = patient; PWT = posterior wall 
thickness. 
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Figure 1. Left ventricular end-diastolic dimension (Dd) at baseline 
evaluation and at the end of follow-up in the good (left) and poor 
(right) response groups. Closed circles and bars indicate the mean 
value + 1 SD. 
two patient groups. Asymmetric septal hypertrophy (interven- 
tricular septal thickness/posterior leftventricular wall thickness 
->1.3) was observed in four patients with a poor response to 
isoproterenol and in 9 patients with a good response. Although 
interventricular septal thickness and posterior left ventricular 
wall thickness showed no statistically significant changes in 
either group during follow-up, the decrease in interventricular 
septal thickness (from 23 + 7 to 16 +_ 3 ram) was greater in the 
poor response group (p = 0.07). Patients 17 and 18, two (50%) 
of the four patients in the poor response group, showed a 
substantial decrease (->5 ram) in interventricular septal thick- 
ness. In three (75%) of the four patients in this group, wall 
thinning involved the septal wall and asymmetric septal hyper- 
trophy diminished. In contrast, no patient in the good response 
group had a change in wall thickness ->5 ram. 
Changes in left ventricular function. At baseline, end- 
diastolic dimension was significantly larger in patients with a 
good than in those with a poor response (46 + 3 vs. 41 -+ 5 ram, 
p < 0.05); however, there was no significant difference between 
groups in fractional shortening at baseline (Table 2). Figure 1 
shows the end-diastolic dimension at baseline evaluation and 
at the end of follow-up in the two groups. In the good response 
group, no significant difference was observed between the 
mean value for end-diastolic dimension at the initial evaluation 
and at the end of follow-up. However, in the poor response 
group, end-diastolic dimension increased markedly from 41 _+ 
5 to 53 _+ 5 mm (p < 0.05), and left ventricular dilation was 
observed in all patients in this group. 
Figure 2 illustrates the fractional shortening at initial 
evaluation and at the end of follow-up. In the good response 
group, fractional shortening increased from 43 _+ 7% to 45 _+ 
7% during follow-up (p = NS). In contrast, in the poor 
response group, mean fractional shortening decreased signifi- 
cantly from 40 +_ 12% to 29 _+ 10% (p < 0.05), and a decrease 
in fractional shortening ->5% was observed in all subjects. 
Thus, both an increase in end-diastolic dimension and a 
decrease in fractional shortening were observed in all four 
subjects in the poor response group. At the final evaluation, 
FS (%) FS (%) 
701 NS~ 
60 
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Figure 2. Fractional shortening (FS) at baseline valuation and at the 
end of follow-up in the good (left) and poor (right) response groups. 
Closed circles and bars indicate the mean value +_ 1 SD. 
end-diastolic dimension was significantly larger (p < 0.01) and 
fractional shortening was significantly lower in the poor than in 
the good response group (p < 0.01) (Table 2). 
Clinical findings. Clinical characteristics at the initial eval- 
uation. Table 3 summarizes the clinical characteristics of the 
patients in the good response and poor response groups at the 
initial evaluation. There were no statistical differences between 
the two groups in any variable examined. 
Development ofsymptoms. All patients in the poor response 
group were asymptomatic at the initial evaluation; however, 
Patient 17 had marked left ventricular dilation and developed 
Table 3. Clinical Characteristics of Patients in the Good and Poor 
Response Groups at Initial Evaluation 
Good Response Group Poor Response Group 
(n= 14) (n-4) 
Age (yr) 55 _+ 9 54 _+ 5 
Male/female ratio 12/2 4/0 
Diagnosis 
HCM 10 2 
HOCM 0 1 
APH 4 1 
NYHA class 1 14 4 
Chest pain 4 0 
Family history 2 2 
Follow-up eriod (yr) 5.2 -- 2.1 6.0 + 0.4 
Treatment 
Beta-blockers 6 2 
Calcium channel 7 3 
antagonists 
ECG findings 
High QRS voltage* 13 4 
Giant negative Y wave? 9 2 
Atrioventricular block 4 0 
Bundle branch block 1 0 
*S wave in lead V~ + R wave in lead V 5 ->3.5 inV. ?Deeper than -10 ram. 
Data presented are the mean value + 1 SD or number of patients. APH = apical 
hypertrophic cardiomyopathy; ECG = electrocardiographic; HCM= hypertro- 
phic cardiomyopathy; HOCM = hypertrophic obstructive cardiomyopathy; 
NYHA = New York Heart Association functional class. 
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congestive heart failure during follow-up. The left ventricular 
cavity dilated from 38 to 59 mm, fractional shortening de- 
creased from 29% to 17% and interventricular septal thickness 
decreased from 25 to 10 mm during 6 years. Neither atrial 
fibrillation nor other tachyarrhythmias were demonstrated in 
this patient by 24-h ECGs. The evolution from a nondilated 
left ventricle to a dilated poorly contractile ventricle was 
associated with symptomatic deterioration. The other patients 
in the poor response group remained asymptomatic during the 
study period. Four (29%) of the 14 patients in the good 
response group had either occasional chest pain or mild 
dyspnea t the initial examination, but the symptoms subsided 
after medical treatment with calcium channel antagonists or 
beta-blockers. 
Electrocardiographic findings. At the initial examination, 
the ECG showed a giant negative T wave (deeper than 
- 10 ram) in 11 patients (61%) and high voltage (S wave in lead 
V I + R wave in lead V 5 -> 3.5 mV) in 17 (94%). At the end of 
follow-up, three patients (75%) in the poor response group 
showed a voltage decrease (S wave in lead Vj + R wave in lead 
Vs) >2.0 mV, whereas 4 (29%) of the 14 patients in the good 
response group showed ecreased voltage. No patient in either 
group had an abnormal Q wave (Q wave duration ->0.04 s, Q/R 
ratio ->0.25) at the initial evaluation. Five patients in the good 
response group had a conduction disturbance: One patient had 
complete right bundle branch block, whereas the other four 
had first degree atrioventricular block. Two patients in the 
poor response group (Patients 17 and 18) had no conduction 
disturbance at the initial examination but developed left 
bundle branch block during follow-up. 
Family history of idiopathic ardiomyopathy. Four patients 
had a family history of left ventricular hypertrophy. Patients 15 
and 17, two (50%) of the four patients in the poor response 
group, had a family history of ECG abnormalities such as high 
voltage and giant negative T waves. The younger brother of 
Patient 15 had died suddenly at age 41 years. Patients 3and 5, 
2 (14%) of the 14 patients in the good response group, had a 
family history of left ventricular hypertrophy and premature 
sudden death. The mother of Patient 3 had left ventricular 
hypertrophy and had died suddenly. Patient 5 had eight 
brothers, two of whom had left ventricular hypertrophy and 
died suddenly when they were young. Although there was no 
statistical difference between the two study groups with regard 
to family history (p = 0.19), a greater proportion of the poor 
responders had a family history of cardiomegaly and sudden 
death. No patient in this study had a family history of idio- 
pathic dilated cardiomyopathy. 
Discussion 
It has been considered that in hypertrophic cardiomyopa- 
thy, inappropriate hypertrophy and systolic function do not 
worsen even in the end stage; however in, a few patients, 
hypertrophic cardiomyopathy has been reported to evolve into 
a phase characterized by systolic dysfunction and left ventric- 
ular dilation, that is, a phase resembling dilated cardiomyop- 
athy. The morphologic and functional changes observed in 
patients with hypertrophic cardiomyopathy are still controver- 
sial (11-15). In the present study, 4 of the 18 patients with 
hypertrophic cardiomyopathy showed progressive l ft ventric- 
ular cavity dilation and systolic impairment. Because of the 
image resolution limitations of echocardiography, wecould not 
evaluate the changes in left ventricular function <5 mm or 
<5%. We excluded from the analysis of data one patient 
whose echocardiographic recordings were poor at the initial 
evaluation; therefore, we evaluated left ventricular perfor- 
mance in only 17 patients with hypertrophic cardiomyopathy. 
The monitoring period may have been too short to detect 
changes in systolic function and cavity dimensions that might 
have occurred in some patients before or after the follow-up 
study, or both. Hence, we did not identify left ventricular 
morphologic hanges that might have occurred in some pa- 
tients before or after, or both, the follow-up study. Further 
follow-up studies are necessary to clarify their clinical course. 
No correlation was found between age, gender, length of 
follow-up, ECG findings or severity of presenting symptoms 
and the prognosis of left ventricular function. Nagata et al. (16) 
mentioned that an increase of enzymes leaked from the 
myocardium ight suggest degeneration f heart muscle cells 
in patients with hypertrophic cardiomyopathy. However, lactic 
dehydrogenase and creatine kinase levels were within normal 
limits at the initial diagnosis and during follow-up in our 
patients (data not shown). Beder et al. (17) described a child 
with hypertrophic ardiomyopathy whose condition evolved 
into a phase resembling dilated cardiomyopathy after treat- 
ment with a beta-adrenergic antagonist (propranolol). In the 
present study there was no statistically significant correlation 
between the administration f any drug and the evolution of 
disease. 
On the basis of exercise stress thallium-201 myocardial 
scintigraphic studies, O'Gara et al. (18) suggested that myo- 
cardial perfusion abnormalities were associated with left ven- 
tricular dysfunction and diltation. Thallium-201 myocardial 
scintigraphy at rest was performed in one of our patients 
(Patient 17) who demonstrated overt congestive heart failure 
during follow-up. In this patient, perfusion abnormalities were 
not observed at the initial study but were detected in the 
inferior and septal walls when heart failure developed. This 
finding supports the observation made by O'Gara et al. 
Although myocardial ischemia in patients with typical hy- 
pertrophic ardiomyopathy and normal epicardial coronary 
arteries has been reported by many investigators (19-21), the 
relation between myocardial ischemia and left ventricular 
function has not been clarified. In our patients, coronary 
angiography demonstrated nosignificant coronary artery ste- 
nosis and the exercise stress test showed no ischemic ST 
segment depression. Moreover, no patient reported chest pain 
and no ischemic findings were observed in the poor response 
group. We therefore believe that myocardial ischemia is prob- 
ably not the main etiologic factor in the transformation f 
cardiac morphology. Except for the response to isoproterenol 
echocardiography, we observed no characteristic features at 
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the initial evaluation that might allow prediction of the evolu- 
tion from hypertrophic cardiomyopathy to a phase resembling 
dilated cardiomyopathy, and involvement of external factors 
such as myocarditis or drugs was ruled out in these patients. It
appears that hypertrophic cardiomyopathy includes asubgroup 
of cardiomyopathies that tend to evolve into dilated cardiomy- 
opathy. 
Recently, several mutations in the beta-myosin heavy chain 
gene have been demonstrated (22-25) to cause hypertrophic 
cardiomyopathy. Cuda et al. (26) demonstrated that mutant 
cardiac myosin purified from skeletal muscles of patients with 
hypertrophic cardiomyopathy shows abnormality in vitro. The 
impaired response to stimulation with isoproterenol in our 
patients might be related to the abnormalities ofbeta-myosin 
heavy chain. Unfortunately, we did not have a sufficient 
number of patients who had a family history of left ventricular 
hypertrophy toperform a definitive analysis of the prognostic 
value of genetic transmission of evolution from hypertrophic 
cardiomyopathy to a phase resembling dilated cardiomyopa- 
thy. Further longitudinal studies involving biochemical re- 
search are needed to clarify the underlying mechanisms of the 
association between response to adrenergic agonists and sub- 
sequent left ventricular dilation with systolic dysfunction. 
Conclusions. No marked changes in echocardiographic 
findings were observed uring follow-up in the good response 
group, whereas all four patients in the poor response group 
showed functional and morphologic hanges. Isoproterenol 
stress echocardiography allowed us to predict evolution from 
hypertrophic cardiomyopathy to the phase resembling dilated 
cardiomyopathy in patients with early stage hypertrophic car- 
diomyopathy. The involvement of external factors was ruled 
out in these patients. These results suggest that hypertrophic 
cardiomyopathy includes a subgroup of cardiomyopathies that 
resemble dilated cardiomyopathy. 
We thank Takeshi Inaba and Masako Takasaki for technical assistance. 
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